Systemlord
Member
Jardiance causes vitamin B12 deficiency, iron deficiency and decreases 1,25-dihydroxyvitamin D.
Jardiance side effect: Iron deficiency - eHealthMe
We study 55617 people who take Iron deficiency or have Jardiance. No report of Iron deficiency is found in people who take Jardiance.
www.ehealthme.com
Jardiance and Iron deficiency - a phase IV clinical study of FDA data
Summary:
Iron deficiency is reported only by a few people who take Jardiance.
Jardiance side effect: Vitamin b12 deficiency - eHealthMe
An AI-powered real world drug study: Vitamin b12 deficiency is found as a side effect among people who take Jardiance (empagliflozin)
www.ehealthme.com
Jardiance and Vitamin b12 deficiency - a phase IV clinical study of FDA data
Summary:
Vitamin b12 deficiency is reported only by a few people who take Jardiance.
Effects of empagliflozin on markers of calcium and phosphate homeostasis in patients with type 2 diabetes - Data from a randomized, placebo-controlled study - PubMed
Empagliflozin treatment of patients with T2D transiently increases serum phosphate, PTH and FGF23, and decreases 1,25-dihydroxyvitamin D. This might reflect a temporal increase of sodium driven phosphate reabsorption in the proximal tubule of the kidney caused by increased sodium availability in...
pubmed.ncbi.nlm.nih.gov
Methods: In this placebo-controlled, randomized, double-blind study patients with T2D were randomized to empagliflozin 10 mg (n = 20) or placebo (n = 22). Biomarkers of calcium and phosphate homeostasis were assessed before, and after 3 days and 3 months of treatment.
Results: After 3 days of treatment empagliflozin significantly increased serum levels of phosphate (baseline: 1.10 ± 0.21 mmol/L; day 3: 1.25 ± 0.23 mmol/L; p = 0.036), parathyroid hormone (PTH) (baseline: 57.40 ± 30.49 pg/mL; day 3: 70.23 ± 39.25 pg/mL; p = 0.025), fibroblast growth factor 23 (FGF23) (baseline: 77.92 ± 24.31 pg/mL; day 3: 109.18 ± 58.20 pg/mL; p = 0.001) and decreased 1,25-dihydroxyvitamin D (baseline: 35.01 ± 14.01 ng/L; day 3: 22.09 ± 10.02 mg/L; p < 0.001), while no difference of these parameters was recorded after 3 months of treatment. Empagliflozin had no significant effects on serum calcium and markers of bone resorption (collagen type 1 β-carboxy-telopeptide = β-CTX) or formation (osteocalcin) after 3 days and 3 months of treatment.
Conclusions: Empagliflozin treatment of patients with T2D transiently increases serum phosphate, parathyroid hormone and fibroblast growth factor, and decreases 1,25-dihydroxyvitamin D. This might reflect a temporal increase of sodium driven phosphate reabsorption in the proximal tubule of the kidney caused by increased sodium availability in response to SGLT2 inhibition.
Last edited: